Get to know our clinical trials
Phase I/II clinical trial of RPTR-1-201, a bispecific T-cell receptor therapy, in patients with advanced solid tumors.
THE MAIN GOAL OF THIS CLINICAL RESEARCH TRIAL IS TO DETERMINE WHETHER THE INVESTIGATIONAL DRUG, RPTR-1-201, IS SAFE AND WHAT SIDE EFFECTS IT MAY CAUSE. IN SOME PARTS OF THE TRIAL, RPTR-1-201 WILL BE GIVEN ALONE, AND IN OTHER PARTS, IT WILL BE GIVEN TOGETHER WITH ANOTHER CANCER DRUG CALLED PEMBROLIZUMAB. THE GOAL IS TO ASSESS THE SAFETY OF RPTR-1-201 WHEN USED ALONE AND WHEN USED TOGETHER WITH PEMBROLIZUMAB.
Technical Summary
- PHASE I/II TRIAL OF RPTR-1-201, A BISPECIFIC T-CELL RECEPTOR THERAPY, IN PATIENTS WITH ADVANCED SOLID TUMORS.
- Code EudraCT: 2025-524010-28-00
- Protocol number: RPTR-1-201-101
- Promoter: Repertoire Immune Medicines
- Molecule/Drug: RPTR-1-201
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.